Two-sided intensity: both new counterparties arriving and existing ones enlarging in the same recent period
The model's full reasoning — Q3 2016 call → NOWe need answer YES/NO based on transcript. Need identify both directions: new paying counterparties actually arrived in recent period (Q3 2016), and existing counterparties enlarged what they take. Management must describe both as already-occurring facts. Let's examine transcript. The call is about clinical development, pipeline, partnerships, trials. "New paying counterparties actually arrived: fresh customers, accounts, partners, or programs that actually signed, ordered, or began transacting in the recent period." Does management describe any new partners/collaborators/income? Let's search. - "we ended quarter with nine programs in clinical development between MacroGenics and partners, with six DART molecules..." - "Two of these molecules are being advanced by partners Janssen and Pfizer..." These are existing partners? - "MacroGenics and Takeda announced conclusion of License and Option Agreement for MGD010, which allowed MacroGenics to regain worldwide rights" - Takeda exited, not new. - "collaboration with Merck" for gastric cancer - existing? It says "conducted in collaboration with our partner, Merck" - but no new signing. - "IND for MGA012 cleared FDA" - new program, not paying counterparty. - "we plan to host R&D Day" etc. Regarding existing counterparties enlarged: "continue to enroll patients and activate two clinical sites" "90% of sites activated" "program approved to expand into first of three Asian countries" - this is about clinical trial sites, not paying counterparties. Maybe "collaboration payments we anticipate receiving" - not actual. Question asks about business intensity from both directions: new paying counterparties actually arrived, and existing counterparties enlarged what they take. The transcript is about a biotech with partners. Need see if management describes new partners signing in recent period or existing partners expanding. I see no such. There is mention of "we have received a lot of in-bound calls about this program" after Takeda, but that's interest, not actual. Also "business development group... engaging various parties" but no deals. No mention of new partnerships signed in Q3. Existing partners? Janssen and Pfizer are ongoing collaborations, but no description of enlarging orders/scope in recent period. The talk is about clinical trial progress, not revenue from counterparties.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| PBR | Petróleo Brasileiro S.A. - Petrobras | Q4 2023 | 2024-03-08 | D |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| VIPS | Vipshop Holdings Limited | Q2 2023 | 2023-08-18 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| CNA | CNA Financial Corporation | Q4 2022 | 2023-02-06 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| OGE | OGE Energy Corp. | Q3 2018 | 2018-11-08 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| DLHC | DLH Holdings Corp. | Q1 2018 | 2018-02-06 | C+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| BCH | Banco de Chile | Q3 2016 | 2016-10-30 | B+ |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
PFIE · Q1 2023 → YESThe question is about whether management describes intensification from BOTH new paying counterparties AND existing ones enlarging what they take, in the recent period, as observed facts. YES Management describes both new arrivals ("new customers," "new opportunities," "several project opportunities," "notable customers" including specific ones like Equitrans Midstream and Enterprise Products) and existing-customer expansion ("repeat orders," "repeat business," "repeat orders from one of the United States’ largest producers," " 85,000 burner management solutions," "large uptick... on retrofits") as already-completed facts in the recent period. They present the combination—widening the customer base while deepening relationships—as the current observed pattern driving the business forward.
EPAM · Q4 2017 → YESThe question is about whether management describes that in the recent period the company's business intensified from BOTH directions at once: new paying counterparties arrived AND existing ones enlarg...YES Management describes both sides occurring together in the recent period: new engagements with clients (including specific examples like the European multinational and Global Health Services Company that started less than 12 months ago) alongside growth within the top 20 existing accounts (more than 18% year-over-year) and even stronger growth outside those 20 (34%). They frame this as an observed pattern of widening and deepening the business now, with continued diversification and expansion across both new and existing relationships.
UNH · Q4 2017 → YESThe question is about whether management describes that in the recent period the company's business intensified from BOTH directions at once: new paying counterparties arrived AND existing ones enlarg...YES Management describes both new paying counterparties (e.g., new states like West Virginia, hospitals using Rally, healthcare transformation alliance with 10 companies, acquisitions like Banmedica and DaVita) and existing ones enlarging (e.g., serving nearly 1 million more seniors in Medicare, 465,000 more in commercial group, strong growth with existing client base for PBM, doubled Rally IDs, 7% same-store growth for SCA, highest Q4 script growth).